Clinical Scorecard: Impact of Early Gestational Maternal Fasting Plasma Glucose on Developmental Delays in Children at Age Two
At a Glance
Category
Detail
Condition
Developmental delay in children at 2 years of age
Key Mechanisms
Maternal fasting plasma glucose (mFPG) level in early gestation and its association with developmental delay
Target Population
Mother–child pairs from the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study in Japan
Care Setting
Prenatal health check-ups and pediatric developmental screening
Key Highlights
mFPG level before 24 gestational weeks was analyzed as both continuous and categorical variables in relation to developmental delay.
No significant association was found between continuous mFPG levels and developmental delay across five developmental domains at age 2.
Low mFPG level (≤70 mg/dL) was associated with lower odds of developmental delay compared to mFPG 71-94 mg/dL, but no increased risk was observed with high mFPG (≥95 mg/dL).
Guideline-Based Recommendations
Diagnosis
Screen for developmental delay in children under 3 years using standardized tools such as the Ages and Stages Questionnaire.
Measure maternal fasting plasma glucose during early gestation (before 24 weeks) as part of prenatal care.
Management
Monitor maternal blood glucose levels during pregnancy to detect overt diabetes and gestational diabetes mellitus (GDM).
Early treatment of GDM diagnosed before 20 weeks may reduce adverse neonatal outcomes.
Monitoring & Follow-up
Conduct approximately 14 prenatal health check-ups including blood glucose testing in early pregnancy.
Follow up on developmental milestones in children at 2 years to identify any delays.
Risks
Pregestational diabetes mellitus and GDM are known risk factors for developmental delays and neurodevelopmental disorders, but early gestational mFPG levels were not associated with increased developmental delay risk in this study.
Patient & Prescribing Data
Pregnant women without pregestational diabetes or GDM and their children at 2 years of age
Early gestational mFPG levels, including elevated levels ≥95 mg/dL, were not linked to increased developmental delays, suggesting that early mFPG alone may not necessitate altered management for developmental delay prevention.
Clinical Best Practices
Incorporate early gestational fasting plasma glucose measurement in routine prenatal care to detect overt diabetes.
Use standardized developmental screening tools like the Ages and Stages Questionnaire at age 2 for early detection of developmental delays.
Recognize that maternal hyperglycemia diagnosed later in pregnancy (24-28 weeks) may have different implications than early gestational glucose levels.
Exclude confounding factors such as maternal smoking and pre-existing diabetes when assessing developmental outcomes.
